Arrowhead Research (ARWR) Tops Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Piper Jaffray Cuts Price Target on Arrowhead Research (ARWR) to $8.00 Following 3Q
August 10, 2016 8:53 AM EDTPiper Jaffray maintained an Overweight rating on Arrowhead Research (NASDAQ: ARWR), and cut the price target to $8.00 (from $13.00), following the company's 3Q earnings report. Arrowhead ended FY3Q:16 with cash of $44.6 million and issued 7.63 million shares at $5.90 per share bringing proforma cash to ~$90 million.... More
Arrowhead Research (ARWR) Prices $45M Private Stock Offering at $5.90/Share
August 9, 2016 9:06 AM EDTArrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) announced that it has priced a private offering of its common stock with gross proceeds expected to be $45 million. The offering was priced at $5.90 per share.
Cantor Fitzgerald & Co. acted as sole placement agent for the offering.
Approximately 7.63 million... More
